Covid-19 in Parkinson's Disease treated by drugs or brain stimulation
Copyright © 2024. Published by Elsevier España, S.L.U..
PURPOSE: Covid-19 has affected all people, especially those with chronic diseases, including Parkinson's Disease (PD). Covid-19 may affect both motor and neuropsychiatric symptoms of PD patients. We intend to evaluate different aspects of Covid-19 impact on PD patients.
METHODS: 647 PD patients were evaluated in terms of PD-related and Covid-19-related clinical presentations in addition to past medical history during the pandemic through an online questioner. They were compared with an age-matched control group consist of 673 individuals and a sample of the normal population consist of 1215 individuals.
RESULTS: The prevalence of Covid-19 in PD patients was 11.28%. The mortality was 1.23% among PD patients. The prevalence of Covid-19 in PD patients who undergone Deep Brain Stimulation (DBS) was 18.18%. No significant association was found between the duration of disease and the prevalence of Covid-19. A statistically significant higher prevalence of Covid-19 in PD patients who had direct contact with SARS-CoV-19 infected individuals was found. No statistically significant association has been found between the worsening of motor symptoms and Covid-19. PD patients and the normal population may differ in the prevalence of some psychological disorders, including anxiety and sleeping disorders, and Covid-19 may affect the psychological status.
CONCLUSION: PD patients possibly follow tighter preventive protocols, which lead to lower prevalence and severity of Covid-19 and its consequences in these patients. Although it seems Covid-19 does not affect motor and psychological aspects of PD as much as it was expected, more accurate evaluations are suggested in order to clarify such effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Neurologia - 39(2024), 3 vom: 29. Apr., Seite 254-260 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salari, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nrleng.2021.07.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370426274 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370426274 | ||
| 003 | DE-627 | ||
| 005 | 20240401233056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nrleng.2021.07.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM370426274 | ||
| 035 | |a (NLM)38553103 | ||
| 035 | |a (PII)S2173-5808(24)00031-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salari, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Covid-19 in Parkinson's Disease treated by drugs or brain stimulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier España, S.L.U. | ||
| 520 | |a PURPOSE: Covid-19 has affected all people, especially those with chronic diseases, including Parkinson's Disease (PD). Covid-19 may affect both motor and neuropsychiatric symptoms of PD patients. We intend to evaluate different aspects of Covid-19 impact on PD patients | ||
| 520 | |a METHODS: 647 PD patients were evaluated in terms of PD-related and Covid-19-related clinical presentations in addition to past medical history during the pandemic through an online questioner. They were compared with an age-matched control group consist of 673 individuals and a sample of the normal population consist of 1215 individuals | ||
| 520 | |a RESULTS: The prevalence of Covid-19 in PD patients was 11.28%. The mortality was 1.23% among PD patients. The prevalence of Covid-19 in PD patients who undergone Deep Brain Stimulation (DBS) was 18.18%. No significant association was found between the duration of disease and the prevalence of Covid-19. A statistically significant higher prevalence of Covid-19 in PD patients who had direct contact with SARS-CoV-19 infected individuals was found. No statistically significant association has been found between the worsening of motor symptoms and Covid-19. PD patients and the normal population may differ in the prevalence of some psychological disorders, including anxiety and sleeping disorders, and Covid-19 may affect the psychological status | ||
| 520 | |a CONCLUSION: PD patients possibly follow tighter preventive protocols, which lead to lower prevalence and severity of Covid-19 and its consequences in these patients. Although it seems Covid-19 does not affect motor and psychological aspects of PD as much as it was expected, more accurate evaluations are suggested in order to clarify such effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Deep brain stimulation | |
| 650 | 4 | |a Enfermedad de Parkinson | |
| 650 | 4 | |a Estimulación cerebral profunda | |
| 650 | 4 | |a Pandemia | |
| 650 | 4 | |a Pandemic | |
| 650 | 4 | |a Parkinson's Disease | |
| 650 | 4 | |a SARS-CoV-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Etemadifar, M |e verfasserin |4 aut | |
| 700 | 1 | |a Zali, A |e verfasserin |4 aut | |
| 700 | 1 | |a Aminzade, Z |e verfasserin |4 aut | |
| 700 | 1 | |a Navalpotro-Gomez, I |e verfasserin |4 aut | |
| 700 | 1 | |a Tehrani Fateh, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia |d 2007 |g 39(2024), 3 vom: 29. Apr., Seite 254-260 |w (DE-627)NLM171204786 |x 2173-5808 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:3 |g day:29 |g month:04 |g pages:254-260 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrleng.2021.07.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 3 |b 29 |c 04 |h 254-260 | ||